Primary central nervous system lymphoma (PCNSL) is a rare subtype of agressive non-hodgkin lymphoma (NHL), and is most commonly of B cell phenotype. The standard treatment is not well established but high dose methotraxate is the most commonly used regimen. Intravenous rituximab (iv Rtx) treatment is integrated into the protocols for systemic B cell lymphomas. However there are mixed results with the use of Rtx. The aim of this meta-analysis is to investigate the role of iv Rtx in the treatment of PCNSL.
PubMed and EBSCOhost databases are searched for rituximab, primary central nervous lymphoma, rituximab, survival. Browsing databases was done in English.
580 patients were included to meta-analysis. Pooled hazard ratio showed that overall survival is correlated with iv Rtx (HR, 0,498; 95% CI, 0,366 - 0,678; p:
In this meta-analysis, we showed that the addition of iv Rtx as part of a treatment protocol for PCNSL has a positive impact on survival.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.